EGFR and lung cancer: KRAS is downstream of EGFR, and hence tumors that contain KRAS mutations were found to be resistant to EGFR TKIs which makes KRAS a good marker for patients who should be excluded from EGFR TKI treatment [25] and are accepted for gene testing of lung cancer.